Helperby Therapeutics

Helperby Therapeutics is pioneering a unique strategy to address the global crisis of anti-microbial resistance by creating synergistic combinations of approved antibiotics. Founded in 2014 by renowned infectious disease expert Prof. Sir Anthony Coates, the company's platform identifies drug pairings that are significantly more potent than single agents and can treat highly resistant bacteria. Its lead programs target complicated urinary tract and skin infections, with a Phase I study completed, and the company is advancing towards Phase III trials. Helperby's model focuses on developing affordable, globally accessible treatments through established regulatory pathways for drug combinations.

Platform for designing synergistic combinations of already approved antibiotics to enhance efficacy, reduce dosing/side-effects, and overcome or delay antimicrobial resistance.

Helperby is unique in focusing exclusively on novel combinations of approved antibiotics for common bacterial infections. It competes with companies developing novel antibiotic molecules (e.g., Entasis, Spero) and other combination approaches, but its specific platform and stewardship-aligned value proposition differentiate it within the anti-infectives space.